Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2020Website:
http://www.tarsusrx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:49:10 GMTDividend
Analysts recommendations
Institutional Ownership
TARS Latest News
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences:
The average price target suggests a potential 38.7% increase for Tarsus Pharmaceuticals (TARS). Although studies have shown this metric may not always be reliable, an increase in earnings estimates could indicate a potential uptick in the stock's value soon.
The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tarsus Pharmaceuticals (TARS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M from the first full quarter of Xdemvy's launch as a treatment for Demodex blepharitis.
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Tarsus Pharmaceuticals, Inc. (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23. TARS completed a follow-on offering in August, raising net proceeds of $99.4M. TARS had $246.9M in cash at the end of Q3'23.
What type of business is Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
What sector is Tarsus Pharmaceuticals in?
Tarsus Pharmaceuticals is in the Healthcare sector
What industry is Tarsus Pharmaceuticals in?
Tarsus Pharmaceuticals is in the Biotechnology industry
What country is Tarsus Pharmaceuticals from?
Tarsus Pharmaceuticals is headquartered in United States
When did Tarsus Pharmaceuticals go public?
Tarsus Pharmaceuticals initial public offering (IPO) was on 16 October 2020
What is Tarsus Pharmaceuticals website?
https://www.tarsusrx.com
Is Tarsus Pharmaceuticals in the S&P 500?
No, Tarsus Pharmaceuticals is not included in the S&P 500 index
Is Tarsus Pharmaceuticals in the NASDAQ 100?
No, Tarsus Pharmaceuticals is not included in the NASDAQ 100 index
Is Tarsus Pharmaceuticals in the Dow Jones?
No, Tarsus Pharmaceuticals is not included in the Dow Jones index
When does Tarsus Pharmaceuticals report earnings?
The next expected earnings date for Tarsus Pharmaceuticals is 09 August 2024